RxDoctor Payments Data

Maria Gonzalez, MD

Internal Medicine · Cutler Bay, FLNPI 1265725238

Payments from drug & device makers

$2,712in general payments, 2019–2025

Across 101 payments — averaging $26.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Cleerly, Inc.$142
  • Abbott$141
  • GSK$135
  • AstraZeneca$125
  • Intersect ENT, Inc.$115
  • plus $141 from 5 others

What the payments were for

  • Food & beverage$2,712100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)81$1,913
Cleerly, Inc.1$142
Abbott2$141
GSK8$135
AstraZeneca1$125
Intersect ENT, Inc.1$115
Pfizer3$58
Argenx US, Inc.1$28
Novo Nordisk1$20
Lilly USA, LLC1$19
Phadia US Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,712 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$10,228
Medicare patients
18
Services billed
178

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban53$68,106
FarxigaDapagliflozin Propanediol40$44,918
JardianceEmpagliflozin19$32,305
XareltoRivaroxaban18$21,998
EntrestoSacubitril/Valsartan18$16,288
BrilintaTicagrelor13$10,208
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,233
SymbicortBudesonide/Formoterol Fumarate30$7,595
Fluticasone-SalmeterolFluticasone Propion/Salmeterol25$3,303
BreynaBudesonide/Formoterol Fumarate16$3,024
LumiganBimatoprost12$2,874
Rosuvastatin Calcium298$2,826
Atorvastatin Calcium367$2,540
Wixela InhubFluticasone Propion/Salmeterol20$2,531
Fenofibrate11$2,484

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$58$68,10653 claims
AstraZenecaFarxiga, Brilinta, Symbicort$125$62,72083 claims
GSKTrelegy Ellipta$135$8,23313 claims
AbbVieLumigan, Synthroid$1,913$4,15725 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Cutler Bay

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →